J100037
Tantalum(V) ethoxide
electronic grade, ≥95%, ≥99.999% metals basis
Synonym(s):
Pentaethoxytantalum, Tantalum pentaethoxide
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
Ta(OC2H5)5
CAS Number:
Molecular Weight:
406.25
EC Number:
228-010-2
MDL number:
Beilstein/REAXYS Number:
3678999
grade
electronic grade
description
J100037
assay
≥95%, ≥99.999% metals basis
form
liquid
refractive index
n20/D 1.487 (lit.)
bp
155 °C/0.01 mmHg
mp
21 °C
density
1.566 g/mL at 25 °C
SMILES string
CCO[Ta](OCC)(OCC)(OCC)OCC
InChI
1S/5C2H5O.Ta/c5*1-2-3;/h5*2H2,1H3;/q5*-1;+5
InChI key
HSXKFDGTKKAEHL-UHFFFAOYSA-N
General description
Please inquire for quantity, pricing, and packaging options.
Still not finding the right product?
Explore all of our products under Tantalum(V) ethoxide
signalword
Warning
hcodes
Hazard Classifications
Flam. Liq. 3
Storage Class
3 - Flammable liquids
wgk
WGK 1
flash_point_f
84.2 °F - closed cup
flash_point_c
29 °C - closed cup
ppe
Faceshields, Gloves, Goggles, type ABEK (EN14387) respirator filter
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
I A Elsum et al.
Oncogene, 33(48), 5523-5533 (2013-11-28)
Lung cancer is the leading cause of cancer deaths worldwide with non small-cell lung cancer (NSCLC) accounting for 80% of all lung cancers. Although activating mutations in genes of the RAS-MAPK pathway occur in up to 30% of all NSCLC
Catharina M L Zegers et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(24), 6389-6397 (2014-10-16)
Increased tumor metabolism and hypoxia are related to poor prognosis in solid tumors, including non-small cell lung cancer (NSCLC). PET imaging is a noninvasive technique that is frequently used to visualize and quantify tumor metabolism and hypoxia. The aim of
Michel van Kruchten et al.
Cancer discovery, 5(1), 72-81 (2014-11-09)
It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer. We performed a feasibility study to assess ER availability before and during fulvestrant. Sixteen